In vitro, ex vivo and in vivo immunopharmacological activities of the isoxazoline compound VGX-1027: Modulation of cytokine synthesis and prevention of both organ-specific and systemic autoimmune diseases in murine models

Ivana Stojanovic, Salvatore Cuzzocrea, Katia Mangano, Emanuela Mazzon, Djordje Miljkovic, Mingjun Wang, Marco Donia, Yousef Al Abed, Joseph Kim, Ferdinando Nicoletti, Stanislava Stosic-Grujicic, Mogens Claesson

Research output: Contribution to journalArticle

Abstract

We have presently studied the in vitro, ex vivo and in vivo immunopharmacological effects of VGX-1027 [(S,R)-3-phenyl-4,5-dihydro-5-isoxasole acetic acid]. This compound reduced the secretion of IL-1β, TNF-α and IL-10 from purified murine macrophages stimulated "in vitro" with lipopolysaccharide (LPS), and it also modified the signaling pathways induced in these cells by LPS entailing reduced activation of NF-κB and p38 MAP kinase pathways along with up-regulation of ERK pathways. VGX-1027 appeared to spare T cell function as it was unable to modify the proliferation and/or secretion of IL-2, IFN-γ and IL-4 induced in purified murine CD4+ T cells from stimulation with either CD3+CD28 or ConA. These effects on macrophages may account for the capacity of VGX-1027 to markedly ameliorate the course of both acute and chronic immunoinflammatory diseases in mice such as carrageenan-induced pleurisy, LPS-induced lethality and type II collagen-induced arthritis. Acute and subacute toxicological studies show that the drug is not toxic at the doses that exert biological effects in these preclinical models. These data warrant additional studies for the potential use of VGX-1027 in the clinical setting.

Original languageEnglish
Pages (from-to)311-323
Number of pages13
JournalClinical Immunology
Volume123
Issue number3
DOIs
Publication statusPublished - Jun 2007

Fingerprint

Autoimmune Diseases
Cytokines
Lipopolysaccharides
MAP Kinase Signaling System
Macrophages
T-Lymphocytes
Pleurisy
Experimental Arthritis
Carrageenan
Poisons
p38 Mitogen-Activated Protein Kinases
Interleukin-1
Acetic Acid
Interleukin-4
Interleukin-10
Toxicology
Interleukin-2
Chronic Disease
Up-Regulation
In Vitro Techniques

Keywords

  • Carrageenan-induced pleurisy
  • LPS-induced lethality
  • TNF-α
  • Type II collagen-induced arthritis
  • VGX-1027

ASJC Scopus subject areas

  • Immunology
  • Immunology and Allergy

Cite this

In vitro, ex vivo and in vivo immunopharmacological activities of the isoxazoline compound VGX-1027 : Modulation of cytokine synthesis and prevention of both organ-specific and systemic autoimmune diseases in murine models. / Stojanovic, Ivana; Cuzzocrea, Salvatore; Mangano, Katia; Mazzon, Emanuela; Miljkovic, Djordje; Wang, Mingjun; Donia, Marco; Al Abed, Yousef; Kim, Joseph; Nicoletti, Ferdinando; Stosic-Grujicic, Stanislava; Claesson, Mogens.

In: Clinical Immunology, Vol. 123, No. 3, 06.2007, p. 311-323.

Research output: Contribution to journalArticle

Stojanovic, Ivana ; Cuzzocrea, Salvatore ; Mangano, Katia ; Mazzon, Emanuela ; Miljkovic, Djordje ; Wang, Mingjun ; Donia, Marco ; Al Abed, Yousef ; Kim, Joseph ; Nicoletti, Ferdinando ; Stosic-Grujicic, Stanislava ; Claesson, Mogens. / In vitro, ex vivo and in vivo immunopharmacological activities of the isoxazoline compound VGX-1027 : Modulation of cytokine synthesis and prevention of both organ-specific and systemic autoimmune diseases in murine models. In: Clinical Immunology. 2007 ; Vol. 123, No. 3. pp. 311-323.
@article{c61fbb8ac4564e35940e5e9902ec10c7,
title = "In vitro, ex vivo and in vivo immunopharmacological activities of the isoxazoline compound VGX-1027: Modulation of cytokine synthesis and prevention of both organ-specific and systemic autoimmune diseases in murine models",
abstract = "We have presently studied the in vitro, ex vivo and in vivo immunopharmacological effects of VGX-1027 [(S,R)-3-phenyl-4,5-dihydro-5-isoxasole acetic acid]. This compound reduced the secretion of IL-1β, TNF-α and IL-10 from purified murine macrophages stimulated {"}in vitro{"} with lipopolysaccharide (LPS), and it also modified the signaling pathways induced in these cells by LPS entailing reduced activation of NF-κB and p38 MAP kinase pathways along with up-regulation of ERK pathways. VGX-1027 appeared to spare T cell function as it was unable to modify the proliferation and/or secretion of IL-2, IFN-γ and IL-4 induced in purified murine CD4+ T cells from stimulation with either CD3+CD28 or ConA. These effects on macrophages may account for the capacity of VGX-1027 to markedly ameliorate the course of both acute and chronic immunoinflammatory diseases in mice such as carrageenan-induced pleurisy, LPS-induced lethality and type II collagen-induced arthritis. Acute and subacute toxicological studies show that the drug is not toxic at the doses that exert biological effects in these preclinical models. These data warrant additional studies for the potential use of VGX-1027 in the clinical setting.",
keywords = "Carrageenan-induced pleurisy, LPS-induced lethality, TNF-α, Type II collagen-induced arthritis, VGX-1027",
author = "Ivana Stojanovic and Salvatore Cuzzocrea and Katia Mangano and Emanuela Mazzon and Djordje Miljkovic and Mingjun Wang and Marco Donia and {Al Abed}, Yousef and Joseph Kim and Ferdinando Nicoletti and Stanislava Stosic-Grujicic and Mogens Claesson",
year = "2007",
month = "6",
doi = "10.1016/j.clim.2007.03.004",
language = "English",
volume = "123",
pages = "311--323",
journal = "Clinical Immunology",
issn = "1521-6616",
publisher = "Academic Press Inc.",
number = "3",

}

TY - JOUR

T1 - In vitro, ex vivo and in vivo immunopharmacological activities of the isoxazoline compound VGX-1027

T2 - Modulation of cytokine synthesis and prevention of both organ-specific and systemic autoimmune diseases in murine models

AU - Stojanovic, Ivana

AU - Cuzzocrea, Salvatore

AU - Mangano, Katia

AU - Mazzon, Emanuela

AU - Miljkovic, Djordje

AU - Wang, Mingjun

AU - Donia, Marco

AU - Al Abed, Yousef

AU - Kim, Joseph

AU - Nicoletti, Ferdinando

AU - Stosic-Grujicic, Stanislava

AU - Claesson, Mogens

PY - 2007/6

Y1 - 2007/6

N2 - We have presently studied the in vitro, ex vivo and in vivo immunopharmacological effects of VGX-1027 [(S,R)-3-phenyl-4,5-dihydro-5-isoxasole acetic acid]. This compound reduced the secretion of IL-1β, TNF-α and IL-10 from purified murine macrophages stimulated "in vitro" with lipopolysaccharide (LPS), and it also modified the signaling pathways induced in these cells by LPS entailing reduced activation of NF-κB and p38 MAP kinase pathways along with up-regulation of ERK pathways. VGX-1027 appeared to spare T cell function as it was unable to modify the proliferation and/or secretion of IL-2, IFN-γ and IL-4 induced in purified murine CD4+ T cells from stimulation with either CD3+CD28 or ConA. These effects on macrophages may account for the capacity of VGX-1027 to markedly ameliorate the course of both acute and chronic immunoinflammatory diseases in mice such as carrageenan-induced pleurisy, LPS-induced lethality and type II collagen-induced arthritis. Acute and subacute toxicological studies show that the drug is not toxic at the doses that exert biological effects in these preclinical models. These data warrant additional studies for the potential use of VGX-1027 in the clinical setting.

AB - We have presently studied the in vitro, ex vivo and in vivo immunopharmacological effects of VGX-1027 [(S,R)-3-phenyl-4,5-dihydro-5-isoxasole acetic acid]. This compound reduced the secretion of IL-1β, TNF-α and IL-10 from purified murine macrophages stimulated "in vitro" with lipopolysaccharide (LPS), and it also modified the signaling pathways induced in these cells by LPS entailing reduced activation of NF-κB and p38 MAP kinase pathways along with up-regulation of ERK pathways. VGX-1027 appeared to spare T cell function as it was unable to modify the proliferation and/or secretion of IL-2, IFN-γ and IL-4 induced in purified murine CD4+ T cells from stimulation with either CD3+CD28 or ConA. These effects on macrophages may account for the capacity of VGX-1027 to markedly ameliorate the course of both acute and chronic immunoinflammatory diseases in mice such as carrageenan-induced pleurisy, LPS-induced lethality and type II collagen-induced arthritis. Acute and subacute toxicological studies show that the drug is not toxic at the doses that exert biological effects in these preclinical models. These data warrant additional studies for the potential use of VGX-1027 in the clinical setting.

KW - Carrageenan-induced pleurisy

KW - LPS-induced lethality

KW - TNF-α

KW - Type II collagen-induced arthritis

KW - VGX-1027

UR - http://www.scopus.com/inward/record.url?scp=34249686065&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34249686065&partnerID=8YFLogxK

U2 - 10.1016/j.clim.2007.03.004

DO - 10.1016/j.clim.2007.03.004

M3 - Article

C2 - 17449326

AN - SCOPUS:34249686065

VL - 123

SP - 311

EP - 323

JO - Clinical Immunology

JF - Clinical Immunology

SN - 1521-6616

IS - 3

ER -